ImmunoFusion Proteins

ImmunoFusion Protein technology takes advantage of the modular structure and long circulating half-lives of human immunoglobulins (antibodies). Company scientists use recombinant DNA methods to covalently fuse therapeutic proteins to the Fc domains of human immunoglobulin gamma proteins (IgGs). IgGs are abundant proteins that have circulating half-lives of up to 21 days in humans. Company scientists have created several cytokine-immunoglobulin fusion proteins that possess the high potency and specificity of their parent cytokine molecules, and the long circulating half-life of the immunoglobulin domain.

Back to Technology